FibroGen CEO Thomas Neff dies suddenly as company drives toward first FDA drug approval
Thomas Neff, who led drug developer FibroGen Inc. into San Francisco's nascent biotech cluster a dozen years ago, died unexpectedly this weekend, the company said in a statement Monday. He was 64.
The statement did not disclose the cause of death.
FibroGen appointed James Schoeneck, most recently CEO of Newark's Depomed Inc. and a nine-year veteran of the FibroGen board, as interim CEO.
Neff founded FibroGen in 1993 and in 2006 moved the company up the Peninsula to Mission Bay, where it was…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news